In the BioHarmony Drug Report Database

"Preview" Icon

Dextroamphetamine saccharate

Adderall, Mydayis (dextroamphetamine saccharate) is a small molecule pharmaceutical. Dextroamphetamine saccharate was first approved as Adderall on 1996-02-13. It is used to treat attention deficit disorder with hyperactivity and narcolepsy in the USA. It is known to target trace amine-associated receptor 1, sodium-dependent dopamine transporter, and sodium-dependent noradrenaline transporter. Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate’s patents are valid until 2029-08-24 (FDA).

 

Trade Name

 

Adderall, Mydayis
 

Common Name

 

dextroamphetamine saccharate
 

ChEMBL ID

 

CHEMBL3989844
 

Indication

 

attention deficit disorder with hyperactivity, narcolepsy
 

Drug Class

 

Image (chem structure or protein)

Dextroamphetamine saccharate structure rendering